Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Chief Legal Officer | September 16, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date September 16, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,617 |
Ending reported balance
After 2026-09-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-16 · Exercise / conversion · Acquired 1,635 · Balance 10,252 Row 2 · 2026-09-16 · Sale · Disposed 1,635 · Balance 8,617 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2035-03-05 | Direct | 58,066 |
Reported balance
After 2026-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-16 · Exercise / conversion · Disposed 1,635 · Balance 58,066 F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2024 Filed Feb 13, 2024 02:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,332 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-014119 · ownership.xml · derivative · entry 7 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,043 Underlying: Common Stock · 1,332 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,996 | $27.50 | $54,890.00 |
DisclosureSEC source: 0000950170-24-014119 · ownership.xml · nonDerivative · entry 6 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,996 | $15.78 | $31,496.88 |
DisclosureSEC source: 0000950170-24-014119 · ownership.xml · nonDerivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 2,916 | $27.50 | $80,190.00 |
DisclosureSEC source: 0000950170-24-014119 · ownership.xml · nonDerivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 2,916 | $8.04 | $23,444.64 |
DisclosureSEC source: 0000950170-24-014119 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,332 | $27.50 | $36,630.00 |
DisclosureSEC source: 0000950170-24-014119 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,332 | $6.49 | $8,644.68 |
DisclosureSEC source: 0000950170-24-014119 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $14.42 | $0.00 |
DisclosureSEC source: 0000950170-23-070015 · ownership.xml · derivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-12-10 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 22:23 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001610717-23-000153 · form4.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 3,750 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 22:23 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | SaleCommon Stock | 3,750 | $20.85 | $78,187.50 |
DisclosureSEC source: 0001610717-23-000153 · form4.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person intended to comply with the prior version of rule 10b5-1. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 22:23 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | Exercise / conversionCommon Stock | 3,750 | $8.04 | $30,150.00 |
DisclosureSEC source: 0001610717-23-000153 · form4.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person intended to comply with the prior version of rule 10b5-1. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 23:23 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001610717-23-000098 · form4.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,375 Underlying: Common Stock · 1,875 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 23:23 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | SaleCommon Stock | 2,247 | $18.31 | $41,143.24 |
DisclosureSEC source: 0001610717-23-000098 · form4.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person intended to comply with the prior version of rule 10b5-1. F2 · price: The transaction was executed in multiple trades in prices ranging from $17.95 to $18.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 23:23 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | Exercise / conversionCommon Stock | 1,875 | $6.49 | $12,168.75 |
DisclosureSEC source: 0001610717-23-000098 · form4.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person intended to comply with the prior version of rule 10b5-1. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:44 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001140361-23-020316 · form4.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 3,750 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:44 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 3,750 | $20.00 | $75,000.00 |
DisclosureSEC source: 0001140361-23-020316 · form4.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,109 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 13, 2022. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:44 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 3,750 | $8.04 | $30,150.00 |
DisclosureSEC source: 0001140361-23-020316 · form4.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 13, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:16 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001567619-23-004430 · doc1.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 1,875 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:16 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 2,248 | $19.30 | $43,386.40 |
DisclosureSEC source: 0001567619-23-004430 · doc1.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,109 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:16 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,875 | $6.49 | $12,168.75 |
DisclosureSEC source: 0001567619-23-004430 · doc1.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 01:23 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0001567619-23-003006 · doc1.xml · derivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-02-09 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · derivative · entry 13 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 3,750 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · derivative · entry 12 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,125 Underlying: Common Stock · 1,875 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 375 | $24.35 | $9,131.25 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 11 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,482 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 100 | $24.49 | $2,449.00 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 10 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 200 | $23.44 | $4,688.00 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 9 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,957 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 2,450 | $22.93 | $56,179.73 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 8 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,157 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The transaction was executed in multiple trades in prices ranging from $22.39 to $23.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,000 | $21.78 | $21,775.00 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 7 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,607 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $21.21 to $22.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 3,750 | $8.04 | $30,150.00 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 6 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 100 | $24.49 | $2,449.00 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 400 | $23.25 | $9,300.00 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,957 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $23.16 to $23.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 975 | $22.71 | $22,147.03 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,357 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $22.13 to $23.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 400 | $21.52 | $8,606.00 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,332 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $20.92 to $21.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,875 | $6.49 | $12,168.75 |
DisclosureSEC source: 0001567619-22-021291 · doc1.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F9 · balance_after: Reflects 2,857 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:38 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001567619-22-017098 · doc1.xml · derivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 18, 2022 Filed Jun 21, 2022 23:54 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001567619-22-013209 · doc1.xml · derivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal and HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-17 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.